N@N

SciClone Pharmaceuticals, Inc.: SciClone Pharmaceuticals, Inc. Added to Russell 3000(R) Index

_{//health-fitness.news-articles.net/content/2009/ .. ceuticals-inc-added-to-russell-3000-r-index.html}
^{Published in Health and Fitness on Tuesday, June 30th 2009 at 3:33 GMT, Last Modified on 2009-06-30 03:33:32 by Market Wire}  

FOSTER CITY, CA--(Marketwire - June 30, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: [ SCLN ]) today announced that it has been added to the Russell 2000® and Russell 3000 Indexes.

The Russell 3000 Index measures the performance of the largest 3000 U.S. companies and is a combination of the Russell 1000® and Russell 2000 Indexes. The Russell 2000 Index is a subset of the Russell 3000 Index, representing approximately 10% of the total market capitalization of that index.

According to Russell Investments, these indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. There is approximately $110 billion of assets indexed to the Russell 3000 Index and investment managers who oversee these funds purchase shares of member stocks according to that company's weighting in the particular index. Membership in the Russell 3000 Index remains in place for one year.

About SciClone

SciClone Pharmaceuticals (NASDAQ: [ SCLN ]) is a profit-driven, global biopharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and expense management. ZADAXIN is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; RP101 in a phase 2 trial for the treatment of pancreatic cancer; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; a phase 2 trial of SCV-07 for the treatment of HCV; and, awaiting approval in China, DC Bead™ for the treatment of liver cancer. For additional information, please visit [ www.sciclone.com ].